Heart failure associated with sunitinib: lessons learned from animal models

Area of Science:

• Cardiology
• Oncology
• Molecular Biology

Background:

• Sunitinib is a potent anticancer drug with known cardiovascular side effects.
• Clinical evidence suggests sunitinib use is associated with cardiac dysfunction.
• Disruption of critical signaling pathways is implicated in sunitinib-induced cardiotoxicity.

Purpose of the Study:

• To review translational data on sunitinib's cardiotoxicity.
• To focus on the role of AMP-activated protein kinase (AMPK), platelet-derived growth factor receptors (PDGFRs), and vascular endothelial growth factor receptors (VEGFRs) in sunitinib's cardiac effects.
• To hypothesize the mechanisms by which sunitinib disrupts these pathways, leading to cardiac dysfunction.

Main Methods:

• Review of basic and translational evidence from animal models of heart failure.
• Focus on three key signaling pathways inhibited by sunitinib: AMPK, PDGFRs, and VEGFRs.
• Analysis of data implicating these pathways in cardiovascular toxicity.

Main Results:

• Sunitinib inhibits multiple signaling pathways crucial for cardiac homeostasis.
• Disruption of AMPK, PDGFRs, and VEGFRs by sunitinib is linked to cardiac dysfunction.
• Evidence suggests a multifactorial molecular basis for sunitinib-induced cardiotoxicity.

Conclusions:

• Sunitinib's inhibition of AMPK, PDGFRs, and VEGFRs is a likely cause of its cardiotoxicity.
• Molecular mechanisms underlying sunitinib-induced cardiac dysfunction involve critical pathways for cardiac homeostasis.
• Further research is warranted to fully elucidate and mitigate sunitinib's cardiovascular side effects.